Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreActive in the last 2 years

Nader N Hanna

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5755-5910; OpenAlex author ID A5017329101. Sources: ClinicalTrials.gov.

Their work

Papers
19
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 3 papers · 2013: 3 papers · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: none · 2026: 1 paper

Papers 19

  1. Survival Impact of Intraoperative Carbon Dioxide Dysregulation in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000001760↗
  2. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. Co-author DOI 10.1002/ijc.34960↗
  3. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Co-author DOI 10.1093/carcin/bgae011↗
  4. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Co-author DOI 10.1093/carcin/bgae025↗
  5. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Co-author DOI 10.1093/carcin/bgae056↗
  6. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  7. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2023.113434↗
  8. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgac092↗
  9. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.1002/ijc.32733↗
  10. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  11. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0511↗
  12. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.18632/oncotarget.10323↗
  13. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗
  14. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-0362↗
  15. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-0209↗
  16. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗
  17. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable panc… Co-author DOI 10.1038/cgt.2012.10↗
  18. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0031507↗
  19. Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Co-author DOI 10.4161/cbt.12.4.16356↗

Trials 1

  1. Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer Principal investigator NCT00711997↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jochen Gaedcke · 14 shared papers, 2012–2024 · strength 1.39
  2. S. Perwez Hussain · 14 shared papers, 2012–2024 · strength 1.39
  3. Azadeh Azizian · 7 shared papers, 2020–2024 · strength 1.12
  4. Yuuki Ohara · 6 shared papers, 2022–2024 · strength 1.03
  5. Michael B. Ghadimi · 6 shared papers, 2013–2024 · strength 0.93
  6. Paloma Moreno · 4 shared papers, 2023–2024 · strength 0.72
  7. Shouhui Yang · 7 shared papers, 2016–2024 · strength 0.71
  8. S. S. Yang · 3 shared papers, 2024 · strength 0.56
  9. Β. Michael Ghadimi · 9 shared papers, 2012–2022 · strength 0.49
  10. H. Richard Alexander · 8 shared papers, 2012–2020 · strength 0.36
  11. Ashley Wetzel · 1 shared paper, 2026 · strength 0.29
  12. Richard Zheng · 1 shared paper, 2026 · strength 0.29
  13. Andrea Feci · 1 shared paper, 2026 · strength 0.29
  14. Harish Lavu · 1 shared paper, 2026 · strength 0.29
  15. Charles J. Yeo · 1 shared paper, 2026 · strength 0.29
  16. Avinoam Nevler · 1 shared paper, 2026 · strength 0.29
  17. Jian Wang · 4 shared papers, 2016–2020 · strength 0.24
  18. Matthias M. Gaida · 4 shared papers, 2016–2020 · strength 0.24
  19. Lin Zhang · 1 shared paper, 2024 · strength 0.18
  20. Jianjun Gao · 1 shared paper, 2024 · strength 0.18
  21. Subrata Sen · 1 shared paper, 2024 · strength 0.18
  22. Nagireddy Putluri · 1 shared paper, 2024 · strength 0.18
  23. Dong Ho Lee · 3 shared papers, 2012–2020 · strength 0.17
  24. Matthew H. G. Katz · 1 shared paper, 2024 · strength 0.13
  25. Floortje van Oosten · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.